This Came True
Two weeks ago, we flagged biotech drift — mid-cap firms under pressure to cut R&D budgets and pivot strategies.
Today, Arsenal Bio confirms the signal: 50% workforce reduction, reallocating capital to clinical advancement.
This is proof-based foresight in action.
The future is not noise — it is patterned, and the patterns are visible.
Codex: DCX-0017.09.19
#Biotech #Foresight #GISMethodStandard
Comments
Post a Comment